NCCN Guidelines® Insights - Rectal Cancer, Version 6.2020
The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines.
Category
  • Rectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Survivorship, Version 2.2020
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment, with the goal of helping healthcare professionals who work with survivors, including those in primary care.
Category
  • Survivorship
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
New Therapeutic Developments in Urothelial Cancer: Clinical Trial Evidence and Expert Guidance
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with urothelial cancer.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Assessment and Management of CAR T-Cell Related Toxicities
CAR T-cell products have the ability to completely change the treatment paradigm for hematologic malignancies.  These therapies are associated with life-threatening toxicities that require rapid intervention. Newly published consensus statements to better define and grade these toxicities should be incorporated into clinical practice.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Kidney Cancer, Version 1.2021
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC).
Category
  • Kidney Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Novel Treatments for Neuroendocrine Tumors
While there is a brand new treatment option for neuroendocrine tumors, it requires a wide array of practical guidance to be given safely and effectively.  Practitioners need to be well versed in patient eligibility, patient preparation for treatment, dosing, administration, and management of side effects.
Category
  • Neuroendocrine Tumors
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Outpatient Care in Hematopoietic Cell Transplant Patients
Educating physicians and oncology nurses about the requirements and advantages of an outpatient HCT program would enable the implementation of this program in their institution and help identify appropriate patients who could benefit from this treatment approach.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Strategies to Reduce Clostridioides Difficile Infection in Hematologic Malignancies
A key component of managing patients with hematologic malignancies, especially those who are HCT recipients, lies in preventing, detecting, and treating C. diff infections by establishing C. diff screening procedures and the appropriate use of anti-infective therapy. Knowledge gained in this arena will support prevention, detection, and timely management of C. diff infections in patients with hematologic malignancies who are HCT recipients.
Category
  • Cancer-related Infections
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation

Pages